Form: SCHEDULE 13G/A

February 13, 2025






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage beneficial ownership in Row 11 above is based on a total of 303,832,404 Ordinary Shares (as defined below) outstanding as of September 30, 2024, as reported in the Issuer's (as defined below) Form 6-K filed with the Securities and Exchange Commission (the "Commission") on November 19, 2024.


SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage beneficial ownership in Row 11 above is based on a total of 303,832,404 Ordinary Shares outstanding as of September 30, 2024, as reported in the Issuer's Form 6-K filed with the Commission on November 19, 2024.


SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage beneficial ownership in Row 11 above is based on a total of 303,832,404 Ordinary Shares outstanding as of September 30, 2024, as reported in the Issuer's Form 6-K filed with the Commission on November 19, 2024.


SCHEDULE 13G


 
TPG GP A, LLC
 
Signature: /s/ Bradford Berenson
Name/Title: Bradford Berenson / General Counsel
Date: 02/13/2025
 
James G. Coulter
 
Signature: /s/ Gerald Neugebauer
Name/Title: Gerald Neugebauer on behalf of James G. Coulter (1)
Date: 02/13/2025
 
Jon Winkelried
 
Signature: /s/ Gerald Neugebauer
Name/Title: Gerald Neugebauer on behalf of Jon Winkelried (2)
Date: 02/13/2025

Comments accompanying signature:  (1) Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Coulter on February 7, 2024 (SEC File No. 001-41617). (2) Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Winkelried on February 7, 2024 (SEC File No. 001-41617).
Exhibit Information

Exhibit 1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.* * Incorporated herein by reference to the Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII, Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David Bonderman, James G. Coulter, Jon Winkelried and Karl Peterson dated as of January 18, 2022, which was previously filed with the Commission as Exhibit 1 to Amendment No. 4 to Schedule 13D filed by TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022 with respect to the shares of common stock of Allogene Therapeutics, Inc.